KEYNOTE-564: Updates in RCC Treatment and Diagnostic Imaging Pearls

Panelists discuss how recent data from the KEYNOTE-564 trial has changed their approaches to treating patients with renal cell carcinoma by implementing adjuvant pembrolizumab therapy for high-risk patients following nephrectomy, citing improved disease-free survival outcomes.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

Now Viewing

EP: 1.KEYNOTE-564: Updates in RCC Treatment and Diagnostic Imaging Pearls

EP: 2.Localized Renal Cell Carcinoma: Current Treatment Considerations

EP: 3.IO-TKI Treatment Regimens in the Treatment of mRCC

EP: 4.Recent Trials Guiding mRCC Treatment

EP: 5.Sequencing Therapies for Patients With Renal Cell Carcinoma

EP: 6.Final Insights in Care for Patients With Renal Cell Carcinoma

Recent Videos

Final Insights in Care for Patients With Renal Cell Carcinoma

Sequencing Therapies for Patients With Renal Cell Carcinoma

Recent Trials Guiding mRCC Treatment

IO-TKI Treatment Regimens in the Treatment of mRCC

Localized Renal Cell Carcinoma: Current Treatment Considerations

Rethinking CAR T Timing: Insights on CAR T Efficacy and Patient Selection

From IMDC Risk Assessments to Sequencing Strategies: Clinical Implications From CLEAR Post Hoc Analyses

From Initial Response to Long-Term Outcomes: Optimizing RCC Treatment Strategies Across the Care Continuum

CAR T in the Real World: Clinician Perspectives on Outcomes, Toxicity, and Patient Management

Clinical Features and Risk Factors: Navigating ASCT vs CAR T Therapy Decisions in R/R LBCL